OBJECTIVE To observe the clinical efficacy and toxic effects of Mabthera （rituximab） in combination with the CHOP （R-CHOP） regimen for treating invasive B-cell non-Hodgkin＇s lymphoma. METHODS A total of 45 patien...OBJECTIVE To observe the clinical efficacy and toxic effects of Mabthera （rituximab） in combination with the CHOP （R-CHOP） regimen for treating invasive B-cell non-Hodgkin＇s lymphoma. METHODS A total of 45 patients with CD20 positive B-cell non- Hodgkin＇s lymphoma were randomly divided into the R-CHOP （22 cases） and CHOP groups （23 cases for controls）. They received the regimens of Mabthera in combination with CHOP or single CHOP therapy respectively. An appraisement of the curative effect could only be performed following 4 cycles of chemotherapy for the 45 patients. Follow-up was conducted to observe the conditions of survival. RESULTS The rate of complete remission （CR） in the R-CHOP group was 68.2%, with a total effective rate of 81.8%, and in the CHOP group these rates were 34.8% and 78.3% respectively. There was a significant difference in comparing the CR rates between the two groups （P 〈 0.05）. The 1, 2 and 3-year overall survival （OS） rates of the RCHOP group were 90.9%, 81.8% and 77.3%, respectively. In the CHOP group, the OS rates were respectively 91.3%, 69.5% and 47.8%. The difference in the 3-year OS between the two groups was significant （P 〈 0.05）. The toxic effects of the two groups were mainly a slight and moderate bone marrow depression and a gastrointesinal reaction, with similar tolerable toxic effects in the two groups （P 〉 0.05）. Adverse effects related to the Mabthera infusions occurred in 6 cases of the R-CHOP group （27.2%）. These effects lessened after symptomatic treatment. CONCLUSION The therapeutic regimen of Mabthera, in combination with CHOP （R-CHOP） has an obvious curative effect for treating invasive B-cell non-Hodgkin＇s lymphoma, with a favorable tolerance. It is highly recommended as the treatment of choice.展开更多
文摘OBJECTIVE To observe the clinical efficacy and toxic effects of Mabthera （rituximab） in combination with the CHOP （R-CHOP） regimen for treating invasive B-cell non-Hodgkin＇s lymphoma. METHODS A total of 45 patients with CD20 positive B-cell non- Hodgkin＇s lymphoma were randomly divided into the R-CHOP （22 cases） and CHOP groups （23 cases for controls）. They received the regimens of Mabthera in combination with CHOP or single CHOP therapy respectively. An appraisement of the curative effect could only be performed following 4 cycles of chemotherapy for the 45 patients. Follow-up was conducted to observe the conditions of survival. RESULTS The rate of complete remission （CR） in the R-CHOP group was 68.2%, with a total effective rate of 81.8%, and in the CHOP group these rates were 34.8% and 78.3% respectively. There was a significant difference in comparing the CR rates between the two groups （P 〈 0.05）. The 1, 2 and 3-year overall survival （OS） rates of the RCHOP group were 90.9%, 81.8% and 77.3%, respectively. In the CHOP group, the OS rates were respectively 91.3%, 69.5% and 47.8%. The difference in the 3-year OS between the two groups was significant （P 〈 0.05）. The toxic effects of the two groups were mainly a slight and moderate bone marrow depression and a gastrointesinal reaction, with similar tolerable toxic effects in the two groups （P 〉 0.05）. Adverse effects related to the Mabthera infusions occurred in 6 cases of the R-CHOP group （27.2%）. These effects lessened after symptomatic treatment. CONCLUSION The therapeutic regimen of Mabthera, in combination with CHOP （R-CHOP） has an obvious curative effect for treating invasive B-cell non-Hodgkin＇s lymphoma, with a favorable tolerance. It is highly recommended as the treatment of choice.
